ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab
Sponsor: Novartis Pharmaceuticals
Collaborators: North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group